Rationale: Injinoryung-San-Gagambang (IJORS) effectively improves hepatic dysfunction caused by polypharmacy in stroke patients.
Introduction
According to nationwide representative research conducted in the Scotland, 12.6% of stroke patients had ≥11 repeat prescriptions as compared with only 1.5% of healthy controls. [1] This burden of medication is commonly defined as polypharmacy, which is linked with a heightened risk of drug-related problems, [2] hepatic disorders. [3] A side effect of clopidogrel, which is commonly used for secondary prevention of ischemic stroke, is increasing liver function levels. [4] The findings of the aforementioned studies suggest that stroke patients may be vulnerable to liver damage because of polypharmacy.
Conventional approaches to hepatic dysfunction in stroke patients are using biphenyl dimethyl dicarboxylate (DDB), [5, 6] silymarin. [7] These medcation normalize elevated blood alanine aminotransferase (ALT) levels in patients with various disorders, such as viral hepatitis and a fatty liver. Previous research reported that DDB lowered blood ALT, whereas it had no effect on aspartate aminotransferase (AST) and gamma-glutamyl transferase (r-GTP). [6] According to a double-blind, randomized, multicenter trial in Korea on the efficacy of DDB, ALT levels were normalized after >4 weeks, and AST levels were unchanged after 12 weeks. [8] Most stroke patients are prescribed numerous drugs because of underlying disease and secondary stroke prevention. [1] Medication adherence can be a burden for these patients.
We describe the cases of 3 stroke patients with abnormal aminotransferase levels who had positive liver outcomes, as assessed by a liver function test (LFT) following treatment with Injinoryung-San-Gagambang (IJORS) for 1 to 3 weeks. This study followed the Case Report guidelines (CARE guidelines).
Case presentation
Three stroke patients with abnormal levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyl transferase (r-GTP) in a liver function test (LFT) received hospital care from January to June 2018 at Wonkwang University Gwangju Korean Medical Hospital (WKUGH, Gwangju, South Korea).
This study was approved by the WKUGH's Institutional Review Board (WKIRB 2018-15) and the patients have provided informed consent for publication of the case.
The serum aminotransferase level was considered normal in accordance with that used in previous studies. [9, 10] The IJORS decoction was prepared by boiling in 500 mL of distilled water for approximately 2 hours until the volume of the solution was concentrated to 100 to 120 mL. The IJORS decoction was administered 3 times daily after meals. The components of IJORS are presented in Table 1 .
Case 1
A 51-year-old man with dizziness who had been diagnosed with cerebellum infarction on December 24, 2017 was admitted to the WKUGH on January 9, 2018. Based on the patient medical records, he had received treatment for pneumonia as a complication of stroke. He had also been diagnosed with hypertension (HTN) and diabetes mellitus (DM). The patient had a history of tuberculosis treatment in 2000 and had made a complete recovery.
From the date of admission, the patient had been taking multiple medications, such as anti-hypertensive drug, hypoglycemic agent, and aspirin, because of baseline disease. The patient's medication list is shown in Table 2 .
On January 18, 2018, he had fever, chills, sputum, cough, and anorexia. The vital signs were as follows: blood pressure (BP) of 150/90 mmHg, body temperature (BT) of 38.5°C, and a pulse rate of 130/min. The results of a chest x-ray pointed to recurrence of pneumonia. 1T hs BID = bis in die, same as twice a day, Cap. = Capsule, hs = Hora somni, same as before sleep, QD = quaque die, same as once a day, Tab. = Tablet, TID = ter in die, same as 3 times a day.
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Thereafter, his vital signs stabilized after 1 week. But pneumonia relapsed again on 2 March. Subsequently, the patient was prescribed P.O. Med (Acetaminopen 325 mg TID, Acetaminopen ER 650 mg TID, Bromhexine Hydrochloride, L-Carbocysteine for Antitussives agents TID).
But the patient had been taking another drug for several days included acetaminophen 300 mg, Pan Cold-S Oral Solution (Dongwha Pharm. CO., Seoul, Republic of Korea), without notifying doctors. As a result, he had an abnormal range of aminotransferase level in a lab test on March 3, 2018.
The patient was prescribed 3 g IJORS prescription (Plus Granule, Hanpoong Pharm, Jeonju city, Korea) for 10 days from 5 March combined with 70 mg silymarin (Legalon Capsule, Bukwang Pharm, Seoul, Korea) and DDB 25 mg (Godex Capsule, CELLTRION Pharm., Seoul, Korea). As the results of the first LFT follow up after treatment revealed no improvement in aminotransferase levels, we changed the IJORS prescription (Plus Granule, Hanpoong Pharm, Jeonju city, Korea) to IJORS decoction (Table 1) . Three weeks after starting the treatment, the patient abnormal aminotransferase levels returned to normal. Figure 1(A) shows a timeline of the patient treatment, and the aminotransferase levels are shown in Fig. 1(B) .
Case 2
An 81-year-old woman with left hemiparesis and dysarthria who had been diagnosed with cerebral infarction at right middle cerebral artery on April 14, 2017 was admitted to the WKUGH on January 9, 2018. The patient was taking aspirin, antihypertensive drugs, and anti-arteriosclerotic agents. The patient reported that she took medication for pruritus and tinea pedis. However, as did not bring the medication with her on the day of admission, we could not confirm the names of the medications or classify the type of drugs. The patient's medication list is shown in Table 2 .
Based on the results of a LFT performed on May 3, 2018, the date of her admission, the patient aminotransferase levels were abnormal. The patient was prescribed IJORS decoction combined with 70 mg silymarin (Legalon Capsule, Bukwang Pharm, Seoul, Korea) and DDB 25 mg (Godex Capsule, CELLTRION Pharm, Seoul, Korea). The same IJORS decoction was prescribed as for Patient 1. After 1 week of the herbal treatment, the patient aminotransferase levels returned to normal. Although the patient r-GTP level was still high, the patient daughter refused continued treatment due to the cost, so the herbal medicine was discontinued. The patient was discharged on 26 May. Thus, it was not possible to follow up the r-GTP level. A timeline of the treatment is given in Fig. 2(A) , and the aminotransferase levels are shown in Fig. 2(B) .
Case 3
A 77-year-old man presented with complaints of right hemiplegia, aphasia, and a history of HTN, DM, and gout diagnosed in 2007.
The patient history included an abdominal aneurysm, a thoracic aortic aneurysm, and surgery on October 31, 2015 following a myocardial infarction. According to the patient wife, On May 11, 2018, the follow up of the patient LFT revealed an extremely abnormal level of aminotransferase. As there was no particular reason for the abnormal aminotransferases level, we consulted the patient wife. His wife reported that the patient consumed a large amount of healthy functional foods, such as Huttuynia cordata, Ginseng, and sockeye salmon.
We instructed the patient to cease consumption of these functional foods and prescribed the same IJORS decoction as in case 1 and 2. After 3 weeks of the herbal treatment, the patient's aminotransferase level returned to normal. The patient r-GTP level remained high. However, due to the insurance coverage period, the patient was discharged on 7 June, and no further data were obtained on his r-GTP level. A timeline of the patient treatment is presented in Fig. 3(A) , and the aminotransferase levels are shown in Fig. 3(B) .
Discussion
We described 3 cases of stroke patients with abnormal aminotransferase levels who were treated using IJORS. All the patients were treated with IJORS 3 times daily for 18.33 ± 7.41 (mean ± standard deviation) days. Blood urea nitrogen (BUN), creatinine clearance (Cr), and bilirubin (total/direct) values were within the normal range before and after treatment ( Table 3 ). All 3 stroke patients had lower aminotransferase levels after treatment. During the follow-up period, no specific adverse effects of the IJORS were reported.
Previous studies of IJORS focused on chronic hepatitis, [11] [12] [13] alcoholic liver disease, [14] liver cirrhosis, [15] postoperative liver dysfunction, [16] cardiovascular system diseases, [17] and hyperlipidemia. [18] To the best of our knowledge, there are no studies on liver dysfunction in stroke patients or in patients taking multiple drugs. It may be difficult to reduce the number of drugs in patients prescribed multiple drugs for underlying diseases like stroke patients who had HTN or DM. In such cases, an alternative approach is needed that can improve the function of the liver faster and more effectively than conventional liver preparations, such as DDB.
Previous studies reported that each of the herbs used in IJORS have been shown to improve liver function and to have hepatoprotective and hypolipidemic effects. [19] [20] [21] For example, research showed that Artemisia capillaris contained effective constituents, such as scoparone, scopoletin, isochlorogenic acid, and pumilaside, for the treatment of hepatitis. [19] Scoparone reduced ALT levels, and isochlorogenic acids markedly inhibited the expression of hepatitis B Surface Antigen (HBsAg), hepatitis B e-antigen (HBeAg), and cccDNA. Poria cocos was effective against acetaminophen-induced liver injury by suppressing NFkB pathway-based apoptosis and inflammatory stress in liver cells. [20] Alismatis rhizoma exhibited hypolipidemic effects and decreased ALT activity. Table 3 Results of bilirubin and renal function test. But also the present study has some limitations. First, the study included only 3 case reports. Therefore, more cases are needed to confirm the effect of IJORS. Second, in 2 cases, the effects of IJORS alone could not be determined, as it was combined with liver preparations. Moreover, this study had a retrospective case series study design. Given the study design and absence of a control group. Therefore, multiple errors and biases may have occurred.
In spite of these limitations, IJORS will be beneficial to the clinical field and physicians who prescribe medicine to stroke patients with liver disease. Furthermore, the stroke patients in the present study with abnormal serum aminotransferase levels due to polypharmacy showed improvements in LFT after IJORS treatment, without any major side effects. These findings point to the potential effectiveness of IJORS, which is generally accepted as safe, as an intervention for liver dysfunction in patients taking multiple drugs. Further studies are needed to confirm the ability of IJORS to improve the liver function of stroke patients taking multiple drugs for the prevention of a second attack or underlying diseases.
